Vermox

Quick links to important sections

Vermox

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vermox

Quick Facts

Property Description
Active ingredient Mebendazole
Form Tablet, oral suspension
Pharmacological class Anthelminthic drug (Benzimidazole derivative)
Common use Addressing parasitic worm infections
Origin Synthetic compound

What Type of Medicine is Vermox (Mebendazole)?

Vermox is a medicine whose active component is Mebendazole, a substance classified as a broad-spectrum anthelminthic drug. This classification means its primary therapeutic role is addressing parasitic infections caused by various types of worms. Mebendazole belongs to the class of anthelmintics and is used to treat infections caused by susceptible worms. This substance is a synthetic compound that is a derivative of the benzimidazole chemical class, signifying a specific chemical group known for its efficacy against these parasites. As a single-ingredient product, its entire action is concentrated through the Mebendazole molecule.

Available Forms and Primary Therapeutic Purpose

Mebendazole is prepared for consumption via the oral route, commonly available to patients as a standard tablet or as an oral suspension. The availability of the oral suspension is particularly noted for facilitating administration to pediatric patient groups who may have difficulty swallowing solid forms. The overall therapeutic purpose of Vermox is directly linked to eliminating parasitic organisms, offering a foundational method for clearing helminthiasis and similar worm infections.

The Basic Physiological Action of Mebendazole

The core mechanism defining Mebendazole's function involves a dual-action approach that selectively targets the parasite's survival. The compound works by interfering with the worms' ability to absorb the necessary nutrient glucose while simultaneously disrupting their internal cell structure, specifically by inhibiting the formation of microtubules. This highly selective physiological action results in the progressive depletion of the parasite's energy and structural integrity, leading to its effective elimination from the body. This targeted mechanism limits its influence on host cells, focusing the medicinal effect on the parasitic organisms.

Regulatory References

  1. NIH/NLM
  2. MedlinePlus Drug Information

What side effects are possible with Vermox?

Possible Side Effects and Safety Information

The safety profile of mebendazole (Vermox) details adverse reactions organized by the body system affected and their reported frequency, as documented by governmental regulatory authorities.

Commonly Reported Adverse Reactions

The most frequent side effects reported during clinical use primarily involve the gastrointestinal system and are classified as common (occurring in ge 1/100 people). These include abdominal pain and diarrhea.

Rare and Serious Adverse Reactions

Adverse reactions classified as rare (occurring in <1/1,000 people) are more systemic and clinically significant. These reported effects span several system-organ classes:

  • Blood and Lymphatic System Disorders: Reports include serious hematological reactions such as neutropenia and agranulocytosis (severe decrease in white blood cells), particularly associated with prolonged use.
  • Skin and Immune System Disorders: Rare but severe skin reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been documented in post-marketing surveillance. Hypersensitivity reactions and hepatitis (liver inflammation) have also been reported.
  • Nervous System Disorders: Convulsions have been reported, primarily in infants below one year of age.

Population and Contextual Safety Notes

Official labeling includes specific safety considerations related to patient population and duration of use. Due to reports of convulsions, mebendazole is not generally recommended for use in children under one year of age. The potential for adverse effects such as neutropenia and abnormal liver function has been associated with higher doses or long-term continuous use, which may warrant specific monitoring.

High-Level Safety Restrictions

Regulatory documents advise caution regarding certain drug combinations; for example, concomitant use with metronidazole should be avoided due to a documented increased risk of serious skin reactions like SJS/TEN. Caution is also advised in patients with pre-existing liver impairment, as this may affect the drug's concentrations.

Overdose and Emergency Response

Overdose and when to seek help for Vermox (Mebendazole)

The official regulatory profile for mebendazole overdose distinguishes between acute manifestations and serious systemic toxicity linked to prolonged high-dose exposure.

Documented Manifestations and Serious Outcomes

Accidental overdosage may present with acute, non-specific gastrointestinal symptoms, including abdominal cramps, nausea, vomiting, and diarrhoea.

A more serious clinical picture is associated with administering dosages substantially higher than recommended or for prolonged periods. These situations have been linked to severe adverse reactions affecting the blood and major organs, such as neutropenia, agranulocytosis (severe blood disorders), hepatitis, reversible liver function disturbances, and glomerulonephritis (kidney inflammation).

Emergency Response and Supportive Management

Immediate medical attention is required if excessive overdosage is suspected or if any signs of serious toxicity—especially those related to the blood or liver—develop.

Regulatory documents confirm that no specific antidote is known for mebendazole. Therefore, management focuses on supportive treatment. In cases of suspected excessive overdosage or poisoning, procedural steps like gastric lavage may be performed, and activated charcoal may be given. Additionally, symptomatic supportive therapy is administered as appropriate. Furthermore, if the medicine has been used at high or prolonged doses, monitoring of blood counts is required due to the risk of hematologic toxicity. Specific severe events, including respiratory arrest and tachyarrhythmia, have been documented following accidental poisoning in an 8-week-old infant.

Therapeutic Uses of Vermox

What Vermox Treats: Main Uses and Benefits

Vermox (mebendazole) is used to address infections in the gastrointestinal tract caused by certain types of parasitic worms. This medication is available as a treatment option for both single and mixed infections in adult and pediatric populations (typically ages one and older, depending on the formulation).

Its primary approved purpose is to help clear infections involving several common soil-transmitted helminths. These therapeutic domains include managing infestations caused by:

  • Pinworm (Enterobius vermicularis)
  • Whipworm (Trichuris trichiura)
  • Roundworm (Ascaris lumbricoides)
  • Hookworm (Ancylostoma duodenale and Necator americanus)

The goal of treatment is to support the resolution of the parasitic burden. It is a component of managing these common gastrointestinal parasitic conditions.

Quick Facts (Therapeutic Domains)

Condition Addressed Category of Use
Pinworm infection Gastrointestinal parasite management
Whipworm infection Supports infection clearance
Roundworm infection Therapeutic intervention
Hookworm infection Addresses parasitic load

Eligibility and Restrictions for Use

Who Can and Cannot Use Vermox?

The official eligibility profile for mebendazole (Vermox) is defined by mandatory exclusions and conditional restrictions documented in regulatory labeling.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and children aged two years and older (established safety and effectiveness). Certain formulations are approved for children one year and older.
Populations for whom use is not recommended Children under two years of age for routine treatment. Pregnant women (especially in the first trimester).
Populations for whom use is contraindicated Persons with a known hypersensitivity to the drug or excipients. Children below the age of one year (due to a reported risk of convulsions). Pregnant women (according to EMA-aligned documents).

Eligibility-Related Restrictions

Caution is advised for patients with pre-existing hepatic impairment. The concomitant use with metronidazole should be avoided due to regulatory warnings regarding the risk of severe skin reactions. Safety and effectiveness are not established in geriatric patients (65 years and older), and caution should be exercised in breastfeeding women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Vermox (mebendazole) defines specific interactions based on their potential to significantly alter the drug's systemic exposure and includes one combination that is formally restricted.

Interaction Restrictions

The co-administration of mebendazole with Metronidazole must be avoided. This mandatory restriction is officially documented due to a reported association with a risk of severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Pharmacokinetic Exposure Changes

Certain co-medications are officially documented to either increase or decrease the overall plasma concentrations of mebendazole. This is primarily a pharmacokinetic interaction.

Exposure Effect Interacting Substance(s) Official Description
Increased Levels Cimetidine Increases mebendazole plasma concentrations by decreasing its metabolism.
Decreased Levels Phenytoin, Carbamazepine, Fosphenytoin, Primidone Decreases mebendazole levels by increasing its metabolism.

Other Interaction Contexts

The drug's exposure is also influenced by physiological and dietary factors. Impaired hepatic function is officially noted as a physiological condition that may lead to higher plasma levels of mebendazole due to altered clearance. Additionally, a drug-food interaction is documented: administering mebendazole with a high-fat meal results in increased systemic absorption of the drug, which impacts overall exposure.

Mechanism of Action

Mebendazole exerts its effect by binding selectively and with high affinity to the beta-tubulin subunit of the parasite's microtubules. This molecular interaction disrupts the polymerization of alpha- and beta-tubulin dimers, structures required for maintaining the integrity and function of the parasite’s cells . The subsequent interference with microtubule assembly leads to a cessation of microtubule-dependent processes within the parasite, specifically inhibiting cellular glucose uptake. This deficit triggers a mechanistic cascade: the resulting inadequate glucose absorption leads to inhibited ATP synthesis and the irreversible depletion of glycogen stores. The profound energy imbalance ultimately results in the degradation of cellular organelles and impaired cellular function, affecting the parasite’s motility and long-term viability.

Dosage and Administration Information

Vermox (mebendazole) is administered via the oral route, typically available as a chewable tablet. Administration requirements for these solid forms specify that tablets may be chewed completely before swallowing, or they can be crushed and mixed with food. Certain high-strength tablets, such as the 500 mg form, can also be softened in a small amount of water to facilitate ingestion.

The dosage schedule is determined by the specific helminth infection being addressed. For pinworm (Enterobius vermicularis), the regimen consists of a single 100 mg oral dose. Conversely, the protocol for whipworm, roundworm, and hookworm infections typically involves a dose of 100 mg twice daily for a consecutive period of three days. The medication can be taken with or without food, without the need for special fasting or purging procedures.

Administration across different populations is standardized; the same dosing schedules applied to adults are also used for pediatric patients 2 years of age and older for the 100 mg regimen. The total treatment duration lasts one or three days. If a second course of treatment is required due to the absence of a cure, this follow-up is administered after an interval of at least three weeks has passed.

Recent Clinical Evidence

Vermox (Mebendazole): Overview of Clinical Evidence

Clinical evidence primarily supports the use of mebendazole for treating infections caused by parasitic worms, particularly soil-transmitted helminths (STHs), in both adults and children over the age of one. These indications include infections by pinworms (Enterobius vermicularis), roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura), and hookworms (Necator americanus, Ancylostoma duodenale).

Comparative Efficacy

Recent systematic reviews and randomized controlled trials (RCTs) have investigated the comparative efficacy of mebendazole against albendazole (another benzimidazole) in various dosing regimens:

  • Pinworm and Roundworm: Mebendazole demonstrates high efficacy for treating infections caused by pinworms and roundworms, with studies showing high cure rates (CR) and egg reduction rates (ERR) that are generally comparable to albendazole.
  • Hookworm and Whipworm: Research indicates that single-dose mebendazole exhibits lower efficacy against hookworm and whipworm infections compared to albendazole. Triple-dose mebendazole regimens may improve the cure rate for whipworm, but studies suggest the efficacy for hookworm remains low, highlighting a potential need for combination treatments or alternative drugs in endemic areas.

Combination Therapy

Trials have explored combination therapies to improve outcomes against difficult-to-treat infections, specifically whipworm (T. trichiura). The co-administration of mebendazole with other anthelmintics, such as ivermectin, has been shown to increase cure rates and egg reduction rates for whipworm, suggesting its value in co-endemic settings.

Safety Profile

At the dosage recommended for parasitic infections, mebendazole is generally well-tolerated. Common adverse reactions reported in clinical trials include gastrointestinal symptoms such as abdominal pain, diarrhea, and nausea. Serious adverse events, including neutropenia, agranulocytosis, and hepatotoxicity (liver injury), have been reported, primarily in patients receiving higher-than-recommended doses or prolonged treatment durations.

Frequently Asked Questions (FAQ)

Common questions about Vermox (FAQ)

Q: Does Vermox kill the parasites or just stop them from growing?

The core function of mebendazole, the active ingredient, is to target the parasite's survival mechanisms. According to official documents, it works by disrupting the formation of internal structures called microtubules. This action prevents the worm from absorbing essential nutrients like glucose, leading to a profound energy deficit and the parasite’s eventual elimination.


Q: Does Vermox treat all types of intestinal worms?

Official labeling defines the drug's use for specific parasitic infections, including pinworm, roundworm, whipworm, and hookworm. While it addresses these common infections, it is not approved for all types of intestinal parasites, such as tapeworms, in every region. A determination of the appropriate medication is based on the specific type of infection present.


Q: Is there any long-term data on the use of Vermox?

Safety reports indicate that serious adverse effects, such as a severe decrease in white blood cells (agranulocytosis) and liver injury (hepatitis), have been reported in some patients. These events were associated with receiving substantially higher doses or prolonged treatment courses that fall outside of the standard prescribed regimens. This information is derived from reported adverse events associated with non-standard, prolonged use.


Q: What regulatory bodies have approved Vermox?

Vermox (mebendazole) has been approved and regulated by major governmental health authorities across the world. These include the U.S. Food and Drug Administration (FDA), the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada. The drug's approval by these bodies confirms its official standing and validated use in these markets.


Q: How quickly does Vermox start to work after the first dose?

Regulatory patient information indicates that the medication should begin its intended action immediately after consumption. However, the clearance of the infection is not instantaneous. Reports indicate that it may take several days for the clearance process to complete.


Q: Is it common to feel tired or dizzy after taking Vermox?

Official adverse event lists include reports of dizziness and drowsiness among the possible side effects associated with the drug. These reactions are not consistently classified as 'common' in all regulatory summaries. Official labeling states that users should be aware of how they react to the medicine before operating machinery or driving.


Q: What over-the-counter pain relievers should be avoided when taking Vermox?

Regulatory patient guidance generally indicates that the use of standard, non-prescription pain relievers, such as paracetamol (acetaminophen) or ibuprofen, is compatible with this medication. Consultation with a pharmacist or healthcare provider is important for any specific drug combination that is planned.


Q: What happens if I miss a dose of Vermox?

Official patient directions provide guidance for handling a missed dose. If the missed dose is remembered within a specific timeframe for a continuous regimen, official guidance states that the patient may take it. Otherwise, the missed dose should be skipped, and the patient should simply continue with the next scheduled dose, avoiding the taking of a double amount.


Q: Do you need a prescription for Vermox?

In the United States, mebendazole is classified as a prescription-only medicine that requires authorization from a healthcare professional. However, the regulatory classification of the drug can vary by country, with some regions making lower-strength versions available over the counter.


Q: What should be done if an overdose of Vermox is suspected?

Reports of taking substantially more than the recommended amount may lead to symptoms such as stomach cramps, nausea, vomiting, and diarrhea. Official guidance indicates that immediate contact with emergency medical services, a healthcare provider, or a Poison Control Center is recommended for assistance.


Q: Is it necessary to treat the whole family if one person has pinworms and is taking Vermox?

Regulatory patient guidance often acknowledges the highly contagious nature of certain infections, such as pinworm. Official patient guidance may reference the recommendation that all members of a household or family undergo treatment simultaneously. This measure is intended to help prevent re-infection.


Q: Are there any non-medicinal things people do while taking Vermox?

Regulatory patient guidance emphasizes the need to complement medication use with specific hygiene practices to prevent the return of the infection. Recommended non-medicinal steps include frequent and careful hand washing, thorough cleaning of bedding and clothing, and avoiding dry sweeping which can stir up dust.


Q: Can Vermox be taken by people with kidney problems?

Official prescribing guidance for mebendazole generally states that no dose adjustment is required for people with kidney impairment. However, individuals with severe kidney issues may require caution. The individual's full medical history should be known by the prescribing healthcare provider.


Q: Does the treatment for threadworm differ from pinworm using Vermox?

Yes, regulatory documents list different administration schedules depending on the specific parasite being treated. For pinworm (Enterobius vermicularis), a single administration is typically cited. For threadworm (Strongyloides stercoralis), a regimen involving administration over a three-day period is generally necessary, as defined in official documents.

How should Vermox be stored and disposed of?

Storage and Disposal of Vermox (Mebendazole)

Vermox tablets and oral suspension must be stored according to regulatory specifications to maintain stability.

Official Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Protection The oral suspension must not be frozen. Keep away from excessive heat, moisture, and direct light.
Container Rule Keep the medicine in its original container and ensure it is tightly closed.
Child Safety Store Vermox out of the sight and reach of children.

Disposal Instructions

Expired or unused Vermox should not be disposed of in household waste or wastewater. Disposal must be conducted in accordance with local, regional, and national regulations to ensure environmental protection, often requiring return to a pharmacy or approved collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vermox found in:

A-Z Index: